- About
- Programs
- News and Events
- eRequest
Announcements
(WASHINGTON, April 17, 2024) –The ASH Research Collaborative (ASH RC) and the Reagan-Udall Foundation for the Food and Drug Administration (FDA Foundation) are launching the Real-World Evidence Consortium for Sickle Cell Disease (SCD) to develop…
(March 6, 2024) The Reagan-Udall Foundation for the FDA has announced new officers and two new members of its Board of Directors.
Adrian F. Hernandez, MD, MHS, a Board member since 2019, has been elected to serve as the Board’s Vice Chair. Debra L.…
What: The Reagan-Udall Foundation for the FDA will host a public workshop to explore primary disease activity biomarkers in rare genetic diseases. Attendees will hear perspectives from patient advocates, researchers, regulators, and representatives…
Coverage
In September 2022, per the request of the FDA Commissioner, Dr. Robert Califf, an independent expert panel facilitated by the Reagan-Udall Foundation began an operational evaluation of the agency’s Center for Tobacco Products (CTP).
Read more
In collaboration with the US Food and Drug Administration (FDA), the Reagan-Udall Foundation for the FDA, is today hosting a hybrid public workshop on "Understanding Current Use of Ketamine for Emerging Areas of Therapeutic Interest."
Read more
This annual report provides an update on FDA's work to support medical countermeasure-related public health preparedness and response efforts.
Read more